Oruka Therapeutics, Inc.
ORKA
$111.04
$2.922.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.05M | 23.54M | 21.41M | 19.44M | 18.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.08M | 133.40M | 122.05M | 117.94M | 113.28M |
| Operating Income | -155.08M | -133.40M | -122.05M | -117.94M | -113.28M |
| Income Before Tax | -132.89M | -116.25M | -105.43M | -101.63M | -99.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -132.89 | -116.25 | -105.43 | -101.63 | -99.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.89M | -116.25M | -105.43M | -101.63M | -99.98M |
| EBIT | -155.08M | -133.40M | -122.05M | -117.94M | -113.28M |
| EBITDA | -154.94M | -133.29M | -121.97M | -117.86M | -113.22M |
| EPS Basic | -2.03 | -1.93 | -1.85 | -1.89 | -2.80 |
| Normalized Basic EPS | -1.54 | -1.49 | -1.45 | -1.51 | -2.27 |
| EPS Diluted | -2.03 | -1.93 | -1.85 | -1.89 | -2.80 |
| Normalized Diluted EPS | -1.54 | -1.49 | -1.45 | -1.51 | -2.27 |
| Average Basic Shares Outstanding | 216.53M | 195.76M | 182.26M | 167.98M | 138.92M |
| Average Diluted Shares Outstanding | 216.53M | 195.76M | 182.26M | 167.98M | 138.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |